Date: 24th December, 2025

To. The Deputy Manager **Department of Corporate Services BSE** Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort. Mumbai-400001.

Sub: Outcome of Board Meeting held on Wednesday, 24th December, 2025.

Ref: Scrip Code: 536565 Scrip Id: NOVELIX

Respected Sir/Madam.

This is to inform that Board of Directors of the Company in its meeting held on 24th December, 2025 at the Registered office of the company i.e., H No: 3-6-237/610, Flat No: 610, 6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029, which commenced at 5:00 P.M. has considered and approved:

1. The allotment of 10,74,000 equity shares of the face value of Rs. 10 each at an issue price of Rs. 20/- each (including a premium of Rs. 10/- per share), fully paid-up upon exercising the option available with warrant holders (person belonging to promoter & non promoter category who have paid Rs. 15/- per warrant i.e. the remaining 75% of issue price) to convert 10,74,000 warrants out of 15,000,000 warrants (Already Converted 6191000) allotted on 10th January, 2025 on preferential basis through Special resolution passed by the shareholders of the Company at the Extra-Ordinary General Meeting on November 18th 2024 and In-Principal approval received from the BSE Limited on December 31st 2024.

Details as required as per Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is attached herewith as annexure I & Annexure II respectively.

The Meeting was concluded at 05:45 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you

Yours sincerely ACEU

For Novelix Pharmaceuticals Limited HYDERABAD

Venkateshwarlu Pulluru (Whole-time director)

DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)



Annexure I

Details as required as per Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015:

- 1. Type of securities proposed to be issued- Equity Shares upon conversion of Warrants.
- 2. Type of Issuance- Preferential issue to Promoter & Non promoters.
- 3. Total Number of Equity Shares Allotted: 10,74,000 Equity Shares issued upon conversion of equal number of Warrants (face value of Rs. 10/-) @ Rs. 20 each.
- 4. Names of the allottees of Equity Shares:

Sr. No.	Name of the Allottees	No. of Equity Shares allotted
	Strategic Investors (Promoter & Promoter Group)	
1.	Narahari Belide	100000
	Strategic Investors (Non- Promoters)	
2.	Chintalapati Sesha Sai Nikhil	492000
3.	KS Swetha	382000
4.	Palakurthi Rakesh	100000

5. Post Allotment of Equity Shares:

- Outcome of Subscription- The Company has received Rs. 1,61,10,000.00/- (Rupees One Crore Sixty-One Lakhs Ten Thousand) (75% of issue price) on allotment of 10,74,000 (Ten Lakhs Seventy-Four Thousand) Equity Shares upon conversion of 10,74,000 warrants out of 1,50,00,000 warrants allotted on 10th January, 2025. (Issue price of Rs. 20/- per equity share)
- Issue Price/ Allotted Price- Issue price of Rs. 20/- each (Face Value Rs. 10/- each + Premium Rs. 10/- each)
- Number of Investors- 4

Consequent to the aforesaid allotment of 10,74,000 (Ten Lakhs Seventy-Four Thousand) Equity Shares; the paid-up equity capital of the Company has increased from Rs. 16,14,10,000.00/- consisting of 1,61,41,000 Equity Shares of Rs. 10/- each to Rs. 172,150,000.00/- consisting of 1,72,15,000 Equity Shares of Rs. 10/- each.

 In case of convertibles-Intimation on conversion of securities or on lapse of the tenure of the instrument: Intimation on conversion of securities.

Novelix Pharmaceuticals limited